Cargando…

Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model

PURPOSE: Hyperuricemia is an independent risk factor for renal damage and can promote the progression of chronic kidney disease (CKD). In the present study, we employ a rat model to investigate the effects of rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor-gamma agonist, on the de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xin, Deng, Jin, Xiong, Chongxiang, Chen, Haishan, Zhou, Qin, Xia, Yue, Shao, Xiaofei, Zou, Hequn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292262/ https://www.ncbi.nlm.nih.gov/pubmed/32606592 http://dx.doi.org/10.2147/DDDT.S247091

Ejemplares similares

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
por: Xiong, Chongxiang, et al.
Publicado: (2021)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

tert-Butylhydroquinone Treatment Alleviates Contrast-Induced Nephropathy in Rats by Activating the Nrf2/Sirt3/SOD2 Signaling Pathway
por: Zhou, Qin, et al.
Publicado: (2019)

Delayed administration of suramin attenuates peritoneal fibrosis in rats
por: Xiong, Chongxiang, et al.
Publicado: (2019)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice
por: Meng, Xiaolu, et al.
Publicado: (2017)

Pharmacological inhibition of autophagy by 3-MA attenuates hyperuricemic nephropathy
por: Bao, Jinfang, et al.
Publicado: (2018)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Evaluation of renal microperfusion in hyperuricemic nephropathy by contrast-enhanced ultrasound imaging
por: He, Li, et al.
Publicado: (2022)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Protective Effect of PPARγ Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats
por: Baghcheghi, Yousef, et al.
Publicado: (2016)

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes
por: Lapice, Emanuela, et al.
Publicado: (2015)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Synthesis and Biological Activity of Piperine Derivatives as Potential PPARγ Agonists
por: Wang, Yanli, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Lymphocyte To High-Density Lipoprotein Ratio As A New Indicator Of Inflammation And Metabolic Syndrome
por: Chen, Haishan, et al.
Publicado: (2019)

Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy
por: Shi, Yingfeng, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
por: Swanson, Christine R., et al.
Publicado: (2013)

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
por: Wu, Yanqiao, et al.
Publicado: (2020)

Visceral Adiposity Index and Chronic Kidney Disease in a Non-Diabetic Population: A Cross-Sectional Study
por: Xiao, Hua, et al.
Publicado: (2020)

Association of Lipid Parameters with the Risk of Chronic Kidney Disease: A Longitudinal Study Based on Populations in Southern China
por: Wang, Xin, et al.
Publicado: (2020)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats
por: Liu, Na, et al.
Publicado: (2017)

Alpha1-Antitrypsin in Urinary Extracellular Vesicles: A Potential Biomarker of Diabetic Kidney Disease Prior to Microalbuminuria
por: Ning, Jing, et al.
Publicado: (2020)

Anti-Hyperuricemic and Uricosuric Potential of Berberis vulgaris in Oxonate-Induced Hyperuricemic Rats
por: Bilal, Muhammad, et al.
Publicado: (2021)

The Product of Red Blood Cells and Hematocrit Can Be Used as a Novel Indicator of Impaired Fasting Blood Glucose Status
por: Feng, Ling, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0v5mh4i3oamqv1sl93aq8bi2g